hydromorphone and Cardiovascular Diseases

hydromorphone has been researched along with Cardiovascular Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amirnovin, R; Koh, JY; Lieu, P; Nelson, LP; Okuhara, C; Rodgers, JW; Sanchez-Pinto, LN1
Bansal, M; Happich, M; Klein, R; Wielage, R; Wilson, K1

Reviews

1 review(s) available for hydromorphone and Cardiovascular Diseases

ArticleYear
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
    Spine, 2013, May-15, Volume: 38, Issue:11

    Topics: Age Factors; Aged; Amitriptyline; Analgesics; Cardiovascular Diseases; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cost-Benefit Analysis; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Gastrointestinal Diseases; Humans; Hydromorphone; Low Back Pain; Markov Chains; Middle Aged; Models, Economic; Naproxen; Ontario; Osteoarthritis; Outcome Assessment, Health Care; Oxycodone; Pregabalin; Pyrazoles; Quality-Adjusted Life Years; Quebec; Sulfonamides; Thiophenes

2013

Other Studies

1 other study(ies) available for hydromorphone and Cardiovascular Diseases

ArticleYear
Implementation of a Risk-Stratified Opioid and Benzodiazepine Weaning Protocol in a Pediatric Cardiac ICU.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2018, Volume: 19, Issue:11

    Topics: Analgesics, Opioid; Benzodiazepines; Cardiovascular Diseases; Female; Humans; Hydromorphone; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Length of Stay; Lorazepam; Male; Methadone; Prospective Studies; Risk Assessment; Severity of Illness Index; Substance Withdrawal Syndrome

2018